2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 244 | ||
| 4 811 | ||
| 1 070 | ||
| 729 | ||
| 3 733 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·41 min sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.
It probably goes like that because people keep starting a new thread, with this stock it is a big mess and confusing. (This has nothing to do with the content) It seems that people have not understood that when you start a new thread every time you have an opinion about this and that, there is a big risk that what is being written will not be read. If we make sure to only start a new thread when a new topic comes up, then we will all have a chance to read what is being written. Because people start a new thread every time they want to say something hither and thither, well, it gets lost and therefore duplicates will appear. With this I hope that people stop starting a new thread every time they want to say something, but use the topic that has been started, this way we can all read what people have in mind. Thanks in advance for the help.
·1 t sitten · MuokattuRead the post below and checked (again) just to be sure with AI (Perplexity) which replied as follows on the clarification of who owns what of patents, whether it is Thor Medical, NucliThera or others: Patents behind Thor Medical's work with radioisotope production are owned by Thor Medical ASA. The old cancer medicine patents from Nordic Nanovector are owned by NucliThera AS. So: Thor Medical ASA mainly owns the patents and patent applications underlying the company's current technology - i.e. the AlphaCycle process for producing alpha emitters such as thorium-228, radium-224 and lead-212 from natural thorium. Current technology Patent applications from 2024-2025 for Thor Medical's production process are registered with Thor Medical ASA as applicant/holder. For example, WO2026008841A1, which concerns the production of useful radionuclides, is listed with Thor Medical ASA as the original and current right holder. Thor Medical AS is building an IP strategy based on patents, trademarks and trade secrets, and that in the first half of 2024 it filed three patent applications related to process and product for alpha-emitter production from natural thorium. A distinction: The Nanovector patents from former Nordic Nanovector - including those related to cancer drug candidates like Betalutin - are no longer owned by Thor Medical. They were transferred to NucliThera AS on December 1, 2023.- ·7 t sitten · MuokattuFollowing the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate entity called Nuclithera AS. Thor Medical AS has a sharing agreement where they receive a % share of a future surplus if Nuclithera succeeds. This without requirements for new equity. Quite unique, and in addition to tax-loss carryforwards of approx. 3 billion, this is a future asset very few are aware of. Now Nuclithera has succeeded in securing funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to deliver highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·41 min sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.It probably goes like that because people keep starting a new thread, with this stock it is a big mess and confusing. (This has nothing to do with the content) It seems that people have not understood that when you start a new thread every time you have an opinion about this and that, there is a big risk that what is being written will not be read. If we make sure to only start a new thread when a new topic comes up, then we will all have a chance to read what is being written. Because people start a new thread every time they want to say something hither and thither, well, it gets lost and therefore duplicates will appear. With this I hope that people stop starting a new thread every time they want to say something, but use the topic that has been started, this way we can all read what people have in mind. Thanks in advance for the help.
- ·1 t sitten · MuokattuRead the post below and checked (again) just to be sure with AI (Perplexity) which replied as follows on the clarification of who owns what of patents, whether it is Thor Medical, NucliThera or others: Patents behind Thor Medical's work with radioisotope production are owned by Thor Medical ASA. The old cancer medicine patents from Nordic Nanovector are owned by NucliThera AS. So: Thor Medical ASA mainly owns the patents and patent applications underlying the company's current technology - i.e. the AlphaCycle process for producing alpha emitters such as thorium-228, radium-224 and lead-212 from natural thorium. Current technology Patent applications from 2024-2025 for Thor Medical's production process are registered with Thor Medical ASA as applicant/holder. For example, WO2026008841A1, which concerns the production of useful radionuclides, is listed with Thor Medical ASA as the original and current right holder. Thor Medical AS is building an IP strategy based on patents, trademarks and trade secrets, and that in the first half of 2024 it filed three patent applications related to process and product for alpha-emitter production from natural thorium. A distinction: The Nanovector patents from former Nordic Nanovector - including those related to cancer drug candidates like Betalutin - are no longer owned by Thor Medical. They were transferred to NucliThera AS on December 1, 2023.
- ·7 t sitten · MuokattuFollowing the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate entity called Nuclithera AS. Thor Medical AS has a sharing agreement where they receive a % share of a future surplus if Nuclithera succeeds. This without requirements for new equity. Quite unique, and in addition to tax-loss carryforwards of approx. 3 billion, this is a future asset very few are aware of. Now Nuclithera has succeeded in securing funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to deliver highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 244 | ||
| 4 811 | ||
| 1 070 | ||
| 729 | ||
| 3 733 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
68 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·41 min sittenFrom facebook group: After the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate company called Nuclithera AS. Thor Medical AS has a sharing agreement where they get a % share of a future profit if Nuclithera succeeds. This without requirement for new equity regardless of future share issues in Nuclithera AS. Quite unique, and in addition to the tax losses carried forward of approx 3 billion that Thor Medical AS took over, this is a future asset very few are aware of. Now Nuclithera has succeeded with funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to develop highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.It probably goes like that because people keep starting a new thread, with this stock it is a big mess and confusing. (This has nothing to do with the content) It seems that people have not understood that when you start a new thread every time you have an opinion about this and that, there is a big risk that what is being written will not be read. If we make sure to only start a new thread when a new topic comes up, then we will all have a chance to read what is being written. Because people start a new thread every time they want to say something hither and thither, well, it gets lost and therefore duplicates will appear. With this I hope that people stop starting a new thread every time they want to say something, but use the topic that has been started, this way we can all read what people have in mind. Thanks in advance for the help.
- ·1 t sitten · MuokattuRead the post below and checked (again) just to be sure with AI (Perplexity) which replied as follows on the clarification of who owns what of patents, whether it is Thor Medical, NucliThera or others: Patents behind Thor Medical's work with radioisotope production are owned by Thor Medical ASA. The old cancer medicine patents from Nordic Nanovector are owned by NucliThera AS. So: Thor Medical ASA mainly owns the patents and patent applications underlying the company's current technology - i.e. the AlphaCycle process for producing alpha emitters such as thorium-228, radium-224 and lead-212 from natural thorium. Current technology Patent applications from 2024-2025 for Thor Medical's production process are registered with Thor Medical ASA as applicant/holder. For example, WO2026008841A1, which concerns the production of useful radionuclides, is listed with Thor Medical ASA as the original and current right holder. Thor Medical AS is building an IP strategy based on patents, trademarks and trade secrets, and that in the first half of 2024 it filed three patent applications related to process and product for alpha-emitter production from natural thorium. A distinction: The Nanovector patents from former Nordic Nanovector - including those related to cancer drug candidates like Betalutin - are no longer owned by Thor Medical. They were transferred to NucliThera AS on December 1, 2023.
- ·7 t sitten · MuokattuFollowing the merger of Thor Medical AS and Nordic Nanovector ASA in 2024, all the patents of the old Nanovector ended up in a separate entity called Nuclithera AS. Thor Medical AS has a sharing agreement where they receive a % share of a future surplus if Nuclithera succeeds. This without requirements for new equity. Quite unique, and in addition to tax-loss carryforwards of approx. 3 billion, this is a future asset very few are aware of. Now Nuclithera has succeeded in securing funding for an extensive CD37 development pathway based on the old patent. ................................................ NucliThera Awarded NOK 16 Million in Research Council Funding to Advance Next-Generation CD37-Targeted Cancer Therapy October 29, 2026 NucliThera AS is pleased to announce that the Research Council of Norway (Forskningsrådet) has approved funding for its Next-Generation CD37 project under the Innovation Project for the Industrial Sector (IPN) programme. The four-year project, with approximately NOK 16 million in public funding, will support the development of a new generation of targeted radionuclide therapies for hematological cancers. The project focuses on developing novel radioconjugates targeting CD37, a protein expressed on several types of blood cancer cells. By combining humanized antibody-based targeting molecules with lead-212 (²¹²Pb), an alpha-emitting radionuclide, NucliThera aims to deliver highly targeted therapies capable of delivering potent radiation directly to malignant cells while limiting exposure to healthy tissues. Building on NucliThera’s established CD37 antibody platform and previous research, the project will focus on optimizing therapeutic candidates, improving their biological distribution and stability, and evaluating their safety and efficacy in preclinical models. The project will be conducted in collaboration with Oslo University Hospital, combining NucliThera’s expertise in radiopharmaceutical development with established capabilities in preclinical cancer research. Its objective is to identify and characterize a lead therapeutic candidate and generate the preclinical evidence and manufacturing documentation needed to support future clinical development. "This funding represents an important milestone for NucliThera and a strong recognition of the scientific and therapeutic potential of our CD37 platform. It allows us to accelerate the development of next-generation radiopharmaceuticals while strengthening our collaboration with leading Norwegian research institutions," said Roy Larsen, Chairman of the Board and Chief Technology Officer of NucliThera. The award further strengthens NucliThera’s research and development portfolio and supports the company’s long-term strategy of advancing innovative targeted radionuclide therapies toward clinical application. About NucliThera AS: NucliThera is an R&D company developing targeted radionuclide therapies for cancer, including lymphoma and leukaemia. Its research combines therapeutic radionuclides with monoclonal antibodies or small molecules to deliver radiation to cancer cells while limiting damage to surrounding healthy tissue. NucliThera’s research team is jointly led by Chief Scientific Officer Dr Ada RepettoLlamazares, Chief Technology Officer Dr Roy H. Larsen and Chief Medical Officer Professor Emeritus Øyvind S. Bruland. Dr Larsen and Professor Bruland’s pioneering work includes the development of Xofigo, an alpha-emitting therapy for bone metastases from prostate cancer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 6 244 | ||
| 4 811 | ||
| 1 070 | ||
| 729 | ||
| 3 733 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt